Welcome to our dedicated page for Nurix Therapeutics SEC filings (Ticker: NRIX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Nurix Therapeutics, Inc. (Nasdaq: NRIX) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a clinical-stage biopharmaceutical issuer focused on targeted protein degradation medicines, Nurix uses its 10-K, 10-Q and 8-K reports to describe pipeline progress, financing activities, collaborations and governance matters.
Recent Form 8-K filings illustrate the types of information NRIX investors can monitor here. One 8-K details an underwriting agreement for a registered offering of common stock under a shelf registration statement, including intended uses of proceeds such as funding clinical development of the BTK degrader bexobrutideg in chronic lymphocytic leukemia, exploring autoimmune indications, expanding the research pipeline and supporting general corporate purposes. Other 8-Ks report on the initiation of the pivotal DAYBreak Phase 2 study of bexobrutideg in relapsed or refractory CLL/SLL, updated clinical data for NX-1607, and changes to the board of directors and committee roles.
Through this page, users can review current and historical SEC documents related to Nurix’s common stock listed on the Nasdaq Global Market under the symbol NRIX. Filings may cover topics such as results of operations, equity offerings, clinical development milestones, collaboration agreements with partners like Gilead, Sanofi and Pfizer, and appointments or resignations of directors and officers.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand material events without reading every page. Real-time updates from EDGAR ensure that new 8-K, 10-Q, 10-K and other forms appear promptly, while dedicated sections make it easier to locate items related to capital raises, clinical trial disclosures or governance changes. For those tracking insider activity, Form 4 and related ownership filings can also be accessed to see how Nurix’s insiders transact in NRIX shares.
Nurix Therapeutics, Inc. insider transaction: The company’s Chief Legal Officer, identified as the reporting person, exercised an employee stock option to acquire 3,760 shares of Nurix common stock at an exercise price of $1.86 per share on 12/18/2025. The same day, the insider sold 3,560 shares of common stock at a weighted average price of $17.8661 per share and an additional 200 shares at a weighted average price of $18.555 per share.
These transactions were carried out under a previously adopted Rule 10b5-1 trading plan. After these transactions, the reporting person beneficially owned 50,897 shares of Nurix common stock directly and held 12,403 employee stock options. The option exercised on this date had fully vested by August 9, 2023.
Nurix Therapeutics, Inc. reported an insider equity transaction by its Chief Legal Officer, Christine Ring. On 11/24/2025, she exercised an employee stock option to acquire 37,600 shares of common stock at an exercise price of $1.86 per share, then sold 37,600 shares of common stock on the same date at a weighted average price of $17.0664 per share under a pre-arranged Rule 10b5-1 trading plan. Following these transactions, she beneficially owned 50,897 shares of Nurix common stock directly and 16,163 employee stock options.
Nurix Therapeutics (NRIX) reported a director stock option grant on a Form 4. The filing shows 50,000 options to purchase common stock at an exercise price of $12.52, granted on November 6, 2025, with an expiration date of November 6, 2035.
The option vests as to 1/36 of the total shares monthly beginning December 6, 2025 until fully vested on November 6, 2028, subject to continued service. Ownership is reported as Direct.
Nurix Therapeutics (NRIX) filed a Form 3 reporting the initial beneficial ownership status of director Roger Dansey following an event dated 11/06/2025. The filing states that no securities are beneficially owned. The form was filed by one reporting person and signed by an attorney-in-fact under a Power of Attorney.
Nurix Therapeutics appointed Roger Dansey, M.D. to its Board of Directors and to the Board’s Clinical and Commercialization Committee, effective immediately. He will serve as a Class III director with a term expiring at the company’s 2026 annual meeting of stockholders.
Compensation follows the non-employee director program: a pro rata portion of the
Nurix Therapeutics (NRIX) reported an insider transaction by its Chief Financial Officer. On 11/03/2025, the CFO sold 6,284 shares of common stock in an open-market transaction pursuant to a previously adopted Rule 10b5-1 trading plan.
The sale had a weighted average price of $12.5607, with individual sales ranging from $12.32 to $13.14. Following the transaction, the officer beneficially owns 37,592 shares directly.
Nurix Therapeutics (NRIX) Form 4: Chief Financial Officer Hans van Houte reported RSU-to-share conversions and a tax-related sale on 10/30/2025. Multiple RSU tranches converted to common stock at no cost: 2,886, 2,000, 3,750, and 2,858 shares. To cover withholding taxes tied to these vestings, he executed a mandated “sell-to-cover” of 3,130 shares at a weighted average price of $12.7967.
Following these transactions, he beneficially owned 43,876 shares of common stock directly. The RSUs vest quarterly under existing schedules, and each RSU represents the right to receive one share upon vesting.
Nurix Therapeutics (NRIX) reported insider activity by its Chief Legal Officer, Christine Ring. On 10/30/2025, multiple restricted stock unit (RSU) vestings converted into common stock via code “M” totaling 10,532 shares (1,924; 2,000; 3,750; 2,858), each at $0 per the RSU terms. A subsequent sale of 3,644 shares at a weighted average price of $12.7967 was executed to cover tax withholding obligations under a required “sell-to-cover” arrangement.
Following these transactions, the reporting person held 50,897 shares directly. Each RSU represents a right to receive one share upon vesting, with tranches vesting quarterly pursuant to previously granted awards.
Nurix Therapeutics (NRIX) reported an insider transaction by its Chief Scientific Officer on Form 4. On 10/30/2025, multiple restricted stock unit (RSU) vestings were settled into common stock, including 3,207; 2,000; 3,750; and 2,858 shares at $0 per share. The insider also sold 4,087 shares at a weighted average price of $12.7967 to satisfy tax withholding via a mandated “sell to cover.” Following these transactions, the insider directly owned 76,751 shares.
Nurix Therapeutics (NRIX) filed a Form 4 reporting an equity grant to its Chief Scientific Officer. On 10/14/2025, the reporting person received 20,000 restricted stock units (RSUs), each representing a right to receive one share of Nurix common stock.
The RSUs were reported at a price of $0 for the derivative security and are held as direct ownership. The award will vest on the second anniversary of the date of grant, contingent on continuous service through that date, after which shares will be delivered. RSUs do not have an expiration date; they either vest or are canceled prior to vesting.
FAQ
What is the current stock price of Nurix Therapeutics (NRIX)?
What is the market cap of Nurix Therapeutics (NRIX)?
